Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 131Unknown 27Terminated 27Recruiting 21Active not recruiting 14Withdrawn 9Not yet recruiting 4Suspended 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

fludarabine phosphate 2Melphalan 2vactosertib 1ponatinib 1fludarabine 1azathiopurine 1aldesleukin 1Vincristine 1Tacrolimus 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Prednisolone 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Interleukin-2 1Inotuzumab Ozogamicin 1Injections 1Imatinib Mesylate 1IL32 protein, human 1Health Promotion 1Educational Status 1Dexamethasone 1Dasatinib 1Cytarabine 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Cytarabine × Clear all
NCT00991744 2012-10-10

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)

Nordic Society for Pediatric Hematology and Oncology

Phase 3 Suspended
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Neurotoxicity Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡